Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SLO-BID vs AMINOPHYLLINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Relaxes smooth muscle of bronchial airways and pulmonary blood vessels by inhibiting phosphodiesterase, increasing intracellular c AMP, and promoting bronchodilation.
Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.
Treatment of asthma,Treatment of chronic obstructive pulmonary disease (COPD)
Treatment of acute bronchospasm in asthma and COPD,Treatment of apnea of prematurity,Off-label: adjunctive therapy in COPD exacerbations, status asthmaticus
Dose: 300-600 mg orally every 12 hours. Immediate-release: 5 mg/kg loading dose then 3 mg/kg every 6 hours. Extended-release: 10-15 mg/kg/day divided every 12 hours. Titrate to serum theophylline concentration of 5-15 mcg/m L.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.
Terminal elimination half-life: 3-15 hours (mean ~10 hours in adults; 20-30 hours in neonates; 1-5 hours in smokers). Clinically, half-life decreases with smoking, increases with hepatic disease, heart failure, and certain drugs (e.g., cimetidine, ciprofloxacin).
Adults: 7-9 hours (nonsmokers), 4-5 hours (smokers), 10-20 hours (neonates, hepatic impairment, CHF).
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by CYP2E1 and xanthine oxidase.
Hepatic metabolism via CYP1A2 and xanthine oxidase; demethylation and oxidation yield active metabolites (caffeine and 3-methylxanthine).
Renal: 90% as metabolites (caffeine, theobromine, paraxanthine, and unchanged drug; 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine). Biliary/fecal: <10%.
Renal: ~10% unchanged; hepatic metabolism (N-demethylation, oxidation) accounts for >80% of elimination; <1% fecal.
~40% bound to albumin.
Approximately 40-60% bound to albumin in adults; lower in neonates (20-30%) and patients with hepatic disease.
0.45 L/kg (range 0.3-0.7 L/kg). Distributes into total body water; higher Vd in neonates and patients with hepatic cirrhosis.
0.3-0.7 L/kg (average 0.45 L/kg); increased in neonates, cirrhosis, and CHF.
Oral immediate-release: 96-100%; oral sustained-release: 90-100% (relative to immediate-release, with dose dumping risk if formulation is altered).
Oral: ~100% (well-absorbed); Rectal: ~80-100% (variable); IM: ~100% (avoid due to pain and unpredictable absorption).
No routine adjustment needed. Monitor for accumulation in severe impairment (Cr Cl <10 m L/min) and consider reducing dose or extending interval.
No specific dose adjustment required based on GFR; monitor theophylline levels closely in renal impairment.
Child-Pugh Class A: reduce dose by 50%; Class B or C: reduce dose by 50-75% and monitor levels.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 50-75% or consider alternative.
Children 1-9 years: 20-24 mg/kg/day orally divided every 12 hours; children 9-12 years: 20 mg/kg/day; adolescents 12-16 years: 18 mg/kg/day. Use ideal body weight. Adjust based on serum theophylline levels.
Oral: 5 mg/kg/dose every 6 hours; IV loading: 5-6 mg/kg; maintenance: 0.5-0.9 mg/kg/hour for ages 6 months-9 years, 0.4-0.5 mg/kg/hour for ages 9-16 years.
Start at lower end of dosing range (e.g., 300 mg/day) due to decreased clearance. Titrate slowly and monitor serum concentrations. Avoid sustained-release formulations if hepatic impairment present.
Reduce initial dose by 50% (e.g., 0.2-0.3 mg/kg/hour IV) due to decreased clearance; monitor serum theophylline levels and titrate slowly.
Theophylline has a narrow therapeutic index. Severe and fatal toxicities can occur if serum concentrations exceed 20 mcg/m L. Serum levels must be closely monitored during therapy.
No FDA boxed warning exists; however, use caution in patients with acute myocardial injury due to potential arrhythmias.
Serious and life-threatening adverse reactions including seizures and cardiac arrhythmias can occur at serum levels above 20 mcg/m L.,Concomitant use with other xanthine derivatives may increase toxicity.,Use with caution in patients with peptic ulcer, seizures, cardiac disease, or hepatic impairment.
Narrow therapeutic index requiring monitoring of serum theophylline levels; increased seizure risk at high concentrations; arrhythmia risk; caution in heart failure, hepatic impairment, and elderly.
Hypersensitivity to theophylline or any component of the formulation,Uncontrolled seizure disorders,Active gastrointestinal hemorrhage
Hypersensitivity to aminophylline, theophylline, ethylenediamine; uncontrolled arrhythmias; active seizure disorder; peptic ulcer; severe hypertension.
High-fat meals may reduce the rate of absorption but not extent; take consistently with or without food. Avoid charcoal-broiled foods and large amounts of dietary protein, which can increase clearance. Grapefruit juice may increase theophylline levels (minor effect).
Avoid high-fat meals which can decrease absorption and lead to variable serum levels. Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase theophylline toxicity and side effects. Charcoal-broiled foods and a high-protein, low-carbohydrate diet may increase clearance of theophylline. Consistently maintain dietary habits to avoid fluctuations in theophylline levels.
SLO-BID (theophylline) is classified as FDA Pregnancy Category C. First trimester: Limited human data, but no clear teratogenic pattern observed. Second and third trimesters: Theophylline crosses the placenta; maternal toxicity may cause fetal adverse effects such as transient tachycardia, jitteriness, and vomiting in neonates. Apnea and seizures reported in cases of maternal overdose.
Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the first trimester, limited data do not indicate a significant increase in major malformations, but the drug should be used only if clearly needed. In the second and third trimesters, theophylline may cause fetal tachycardia, jitteriness, and irritability if maternal levels are high. Near term, accumulation of theophylline in the fetus may lead to neonatal withdrawal (irritability, apnea) and transient tachycardia. Risk is dose-dependent and more pronounced at serum levels >15 mcg/m L.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.6–0.7. The relative infant dose is about 10% of the maternal weight-adjusted dose. Although generally considered compatible with breastfeeding, monitor the infant for signs of irritability, insomnia, or poor feeding, especially at higher maternal doses or with multiple doses.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.7. Infant exposure is estimated to be 1–10% of the maternal weight-adjusted dose. Premature infants or those with impaired clearance are at risk for accumulation and toxicity (irritability, jitteriness, feeding intolerance). Breastfeeding is generally considered acceptable if maternal serum levels are within therapeutic range (5-15 mcg/m L) and the infant is monitored for signs of theophylline toxicity. American Academy of Pediatrics classifies theophylline as compatible with breastfeeding, but caution is advised.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased volume of distribution, potentially requiring dose increases of up to 20–40% to maintain therapeutic serum concentrations. However, clearance decreases near term and postpartum, necessitating dose reduction. Frequent monitoring of serum levels is critical to avoid toxicity.
Pregnancy increases the clearance of theophylline by approximately 20-30% due to increased volume of distribution and hepatic metabolism (especially in the second and third trimesters). Doses may need to be increased by 20-30% to maintain therapeutic serum levels. Frequent monitoring of serum theophylline levels (every 1-2 weeks) is recommended to guide dose adjustments. Postpartum, clearance returns to prepregnancy levels within 2-3 months, so doses should be reduced to avoid toxicity.
SLO-BID (theophylline) requires serum level monitoring (therapeutic range 10-20 mcg/m L); levels >20 may cause toxicity. Use with caution in heart failure, hepatic impairment, or elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides increase levels; rifampin, phenytoin, smoking decrease levels. Sustained-release formulation avoids peak-trough fluctuations and improves adherence.
1. Aminophylline is a bronchodilator that is a combination of theophylline and ethylenediamine; the ethylenediamine component may cause allergic reactions in sensitive individuals. 2. Monitor serum theophylline levels closely (therapeutic range: 10-20 mcg/m L); toxicity can occur at levels >20 mcg/m L with symptoms including nausea, vomiting, tachycardia, and seizures. 3. Use with caution in patients with severe hypoxemia, and treat with diltiazem or benzodiazepines for seizures if they occur. 4. Aminophylline can cause significant drug interactions, particularly with cimetidine, fluoroquinolones, and macrolide antibiotics which increase theophylline levels. 5. In acute asthma exacerbations, aminophylline is typically reserved for cases not responding to inhaled beta-agonists and corticosteroids due to narrow therapeutic index.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Avoid excessive caffeine intake (coffee, tea, cola) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, restlessness, insomnia, or rapid heartbeat.,Do not stop abruptly; taper under medical supervision to prevent rebound symptoms.,Maintain consistent timing; missed doses should be taken if remembered within 2 hours, otherwise skip.
Take this medication exactly as prescribed; do not chew or crush extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, cola) as it may increase side effects such as nervousness and palpitations.,Notify your doctor immediately if you experience nausea, vomiting, irregular heartbeats, or seizures.,Do not smoke or stop smoking without consulting your doctor, as smoking affects how this medication works.,Keep a record of peak flow readings as directed by your healthcare provider.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SLO-BID vs AMINOPHYLLINE, answered by our medical review team.
SLO-BID is a Xanthine Bronchodilator that works by Relaxes smooth muscle of bronchial airways and pulmonary blood vessels by inhibiting phosphodiesterase, increasing intracellular c AMP, and promoting bronchodilation.. AMINOPHYLLINE is a Xanthine Bronchodilator that works by Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SLO-BID and AMINOPHYLLINE depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SLO-BID is: Dose: 300-600 mg orally every 12 hours. Immediate-release: 5 mg/kg loading dose then 3 mg/kg every 6 hours. Extended-release: 10-15 mg/kg/day divided every 12 hours. Titrate to serum theophylline concentration of 5-15 mcg/m L.. The standard adult dose of AMINOPHYLLINE is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SLO-BID and AMINOPHYLLINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SLO-BID is classified as Category C. SLO-BID (theophylline) is classified as FDA Pregnancy Category C. First trimester: Limited human data, but no clear teratogenic pattern observed. Second and third trimesters: Theop. AMINOPHYLLINE is classified as Category C. Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.